D. Boral Capital Secures Strategic Investments from Global Investment Bank ARC Group and an Institutional Investor
21. Januar 2025 08:30 ET
|
D. Boral Capital
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- D. Boral Capital, a premier investment bank focused on high-quality mid-market and growth issuers, today announced it has secured significant strategic...
D. Boral Capital Served as the Sole Underwriter on the IPO of BurTech Acquisition Corp (Nasdaq: BRKH) which Recently Completed an ~$894 Million Business Combination with Blaize, Inc. (“Blaize”)
15. Januar 2025 15:31 ET
|
D. Boral Capital
WASHINGTON and EL DORADO HILLS, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- BurTech Acquisition Corp. (“BurTech”) (NASDAQ: BRKH), a publicly traded special purpose acquisition company, and Blaize,...
D. Boral Capital Served as Placement Agent to Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing
14. Januar 2025 08:00 ET
|
D. Boral Capital
ONTARIO, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nature's Miracle Holding, Inc. (Nasdaq: NMHI) ("Nature's Miracle"), a growing agriculture technology company providing equipment and services to...
D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering
07. Januar 2025 11:18 ET
|
D. Boral Capital
BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the “Company”) (NASDAQ: HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the...
D. Boral Capital Served as Underwriter to Park Ha Biological Technology Co., Ltd. (Nasdaq: PHH) in connection with its $4.8 Million Initial Public Offering
06. Januar 2025 08:00 ET
|
D. Boral Capital
WUXI, China, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the "Company"), a company focused on developing private skincare labels, direct skincare product sales, and...
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
30. Dezember 2024 14:12 ET
|
D. Boral Capital
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
D. Boral Capital Acted as Exclusive Placement Agent to Webuy Global Ltd (Nasdaq: WBUY) in connection with its $3.7 Million Registered Direct Offering
19. Dezember 2024 08:00 ET
|
D. Boral Capital
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Webuy Global Ltd (Nasdaq: WBUY) (the “Company”), a Southeast Asian community-oriented e-commerce retailor with a focus on grocery and travel, on December...
D. Boral Capital Served as Exclusive Placement Agent to FAVO Capital, Inc. (OTC Pink: FAVO) in connection with its $2.0 Million Private Placement
16. Dezember 2024 09:14 ET
|
D. Boral Capital
FORT LAUDERDALE, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- FAVO Capital, Inc. (OTC PINK:FAVO), a leading provider of alternative financing solutions in the Private Credit Sector, today announced that...
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
12. Dezember 2024 08:00 ET
|
D. Boral Capital
CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public...
D. Boral Capital Acted as Exclusive Placement Agent to Baijiayun Group Ltd (Nasdaq: RTC) in connection with its up to $15 Million Convertible Promissory Notes and $50 Million Standby Equity Purchase Agreement
10. Dezember 2024 11:17 ET
|
D. Boral Capital
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ: RTC), a one-stop AI video solution provider, on December 6, 2024, announced that it has...